These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38230320)

  • 1. Guillain-Barré Syndrome following intravesical Bacillus Calmette-Guérin therapy for bladder cancer: a rare and intriguing case report.
    Khor V; Fahmy O; Lee CKS; Khairul-Asri MG
    Cent European J Urol; 2023; 76(4):311-314. PubMed ID: 38230320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Guillain-Barré syndrome caused by intravesical instillation of Bacillus Calmette-Guérin].
    Akan S; Atmaca MC
    Ideggyogy Sz; 2024 Jan; 77(1-2):65-68. PubMed ID: 38321852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Preclinical Therapies for Bladder Cancer Following Bacillus Calmette-Guérin Failure.
    Nazmifar M; Williams C; Naser-Tavakolian A; Heard J; Rosser C; Theodorescu D; Ahdoot M
    J Urol; 2023 Jan; 209(1):32-48. PubMed ID: 36067380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
    Gontero P; Oderda M; Mehnert A; Gurioli A; Marson F; Lucca I; Rink M; Schmid M; Kluth LA; Pappagallo G; Sogni F; Sanguedolce F; Schiavina R; Martorana G; Shariat SF; Chun F
    J Urol; 2013 Sep; 190(3):857-62. PubMed ID: 23545101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer.
    Bajramovic S; Alic J; Skopljak E; Chikha A; Vesnic S; Smajilbegovic V; Aganovic D
    Med Arch; 2020 Apr; 74(2):146-150. PubMed ID: 32577059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urethral fistula and perineal collection during intravesical treatment for non-muscle invasive bladder cancer - A rare complication.
    Ong K; Dyer J; Wilson M; Hayne D
    Urol Case Rep; 2022 May; 42():102003. PubMed ID: 35116226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.
    Fujita N; Hatakeyama S; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Int J Urol; 2022 Aug; 29(8):867-875. PubMed ID: 35577361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Septic Shock After Intravesical Therapy With Bacillus Calmette-Guerin: A Case Report of a Rare Life-Threatening Complication.
    Fernandes PF; Nunes P; Figueiredo A
    Cureus; 2023 Oct; 15(10):e46563. PubMed ID: 37933342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
    Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial.
    van Straten CGJI; Caris C; Grimm MO; Colombel M; Muilwijk T; Martínez-Piñeiro L; Babjuk MM; Türkeri LN; Palou J; Patel A; Bjartell AS; Witjes WPJ; van der Heijden AG; Kiemeney LALM
    Eur Urol Open Sci; 2023 Oct; 56():15-24. PubMed ID: 37822514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
    Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
    J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model.
    Erdoğar N; Iskit AB; Eroğlu H; Sargon MF; Mungan NA; Bilensoy E
    J Nanosci Nanotechnol; 2015 Dec; 15(12):10156-64. PubMed ID: 26682462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
    Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
    Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
    Saluja M; Gilling P
    Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
    Huang Z; Liu H; Wang Y; Zhang C; Xu T
    Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penile lesion with inguinal adenopathy after intravesical Bacillus Calmette-Guerin instillation therapy.
    Aslan G; Sevinc C; Tuna B; Ozkal S; Yorukoglu K
    Indian J Urol; 2013 Jan; 29(1):70-2. PubMed ID: 23671372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.